[{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Macromolecules","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Janssen"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$25.0 million","newsHeadline":"Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0.19,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Chugai","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme Therapeutics \/ Chugai"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LNC-based mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ GC Biopharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Advanced Therapies and A*STAR Announce Partnership to Advance Cell and Gene Therapy in The Asia-Pacific Region","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster Absorption","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight \/ Pfizer"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector\u00ae Platform for CAR-T Therapy","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories"},{"orgOrder":0,"company":"Starpharma","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starpharma Signs New DEP Agreement With MSD","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ MSD","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ MSD"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Series C Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Drive Capital"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Closing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","amount":"$56.1 million","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Secures CNY410M in Series C Round","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi ATU Announces Licensing Agreement with Janssen for TESSA\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV Vectors","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Advanced Therapies \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advanced Therapies \/ Janssen"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$60.7 million","upfrontCash":"Undisclosed","newsHeadline":"SonoThera Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0.059999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belharra Therapeutics Debuts With $130 Million in Funding","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ National Resilience"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd. Possessing the Nucleic Acid Pharmaceutical Element Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Financing","leadProduct":"Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Human Cellular Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ Mirus Bio"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arzeda, the Protein Design Company\u2122, Announces Collaboration with Takeda to Accelerate Protein Biologics Optimization","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Announces Strategic Investment with Samsung Ventures","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Samsung Venture Investment Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Araris Biotech \/ Samsung Venture Investment Corporation"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0.64000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evotec Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Bayer AG"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Receives Gene Therapy Milestone Payment","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicinova \/ Sanofi Genzyme","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ Sanofi Genzyme"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Cannabinoid-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul \/ Synaptogenix"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevolKa Signed Master Service Agreement with Daiichi Sankyo","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ Daiichi Sankyo"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Bio proprietary technology.
Details :
RevolKa will create and deliver highly functional proteins, RK007, in collaboration with Daiichi Sankyo by using its proprietary protein engineering platform technology, called aiProtein.
Details :
Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Details :
The AAV technology was developed by Avigen, which MediciNova acquired in 2009. The milestone payment is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV vector technology that is covered...
Details :
Acuitas’ Lipid Nanoparticle (LNP) technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Details :
The partnership sets out highest ambitions for reaching highest quality and lowest cost levels by introducing Just – Evotec Biologics’ data-driven, fully integrated design capability and continuous manufacturing technology (J.DESIGN) into the field o...
Details :
The proceeds will be used to support the development of next-generation mRNA-based therapeutic products and deploying its extensive portfolio of in-licensed mRNA cell engineering patents through strategic partnerships.
Details :
The net proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate candidates using company's proprietary antibody-drug conjugate (ADC)-linker technology.
Details :
The collaboration will allow Takeda to leverage Arzeda's Intelligent Protein Design Technology™, which has the potential to accelerate the optimization of proteins that can be incorporated into therapeutic products.
Details :
Kytopen and Mirus Bio will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines.
Market Place
Reset All
